EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'New Patent Strengthens Adial's Patent Portfolio and Covers AD04's Unique Ability to Target the Serotonin Transporter Gene for the Potential Treatment of Opioid Use Disorder'
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'New Patent Strengthens Adial's Patent Portfolio and Covers AD04's Unique Ability to Target the Serotonin Transporter Gene for the Potential Treatment of Opioid Use Disorder'
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.